GLP-1 Market Outlook Shows Rapid Growth in Asia-Pacific Due to Expanding Healthcare Infrastructure

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global GLP-1 Market Size, Share & Trends Analysis Report By Type of Molecule (Biologics and Small Molecules), Active Compound Used (Dulaglutide, Liraglutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide and Other Active Compounds), Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist and Short-acting GLP-1 Agonist), Type of Agonist (Single-agonist, Dual-agonist and Tri-agonist), Route of Administration (Oral and Parenteral), Target indication (Alzheimer's Disease, Non-Alcoholic Steatohepatitis, Obesity, Sleep Apnea, Type 2 Diabetes)- Market Outlook And Industry Analysis 2034"

The Global GLP-1 Market is valued at USD 50.0 Billion in 2024, and it is expected to reach USD 141.9 Billion by the year 2034, with a CAGR of 11.1% during the forecast period of 2025-2034..

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2592

Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone produced by the gastrointestinal tract, playing a pivotal role in regulating glucose homeostasis and appetite. GLP-1 receptor agonists are therapeutic agents designed to activate GLP-1 receptors, eliciting multiple clinically relevant effects, including the stimulation of glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release, delayed gastric emptying, and enhanced peripheral glucose uptake. These mechanisms collectively contribute to effective glycemic control in patients with type 2 diabetes, while simultaneously promoting weight reduction-offering a key therapeutic advantage for individuals with obesity or metabolic disorders.

The GLP-1 receptor agonist market encompasses both approved and investigational therapies, including short-acting agents such as exenatide and lixisenatide, as well as long-acting formulations, including semaglutide, dulaglutide, and liraglutide. The advent of oral therapies, such as oral semaglutide (Rybelsus), has further improved patient convenience and accessibility, expanding treatment adoption.

Advancements in next-generation GLP-1 agents, including dual- and tri-agonists like tirzepatide that target multiple hormonal pathways, signify a major progression in the management of metabolic diseases. Market expansion is primarily driven by the rising global prevalence of type 2 diabetes and obesity, combined with the established clinical efficacy, safety profile, and versatility of existing GLP-1 therapies. Continued innovation, active clinical research, and broadened therapeutic indications are expected to sustain the growth trajectory of the GLP-1 receptor agonist market in the foreseeable future.

List of Prominent Players in the GLP-1 Market:
• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The rising global prevalence of type 2 diabetes and obesity is a primary driver of growth in the GLP-1 receptor agonist market. Epidemiological data indicate that diabetes prevalence increased from 3.0% to 4.1%, while obesity rates rose from 32.7% to 40.9% between 2009 and 2020, according to the Journal of the American Medical Association. GLP-1 receptor agonists have consistently demonstrated strong clinical efficacy, including reductions in blood glucose levels, decreases in HbA1c, and meaningful weight loss.

Regulatory approvals, such as semaglutide (Wegovy) for obesity management in addition to diabetes treatment, have expanded the eligible patient population, thereby accelerating market adoption. Enhancements in insurance coverage and affordability are further facilitating access to these therapies. Moreover, technological advancements in drug delivery-such as oral formulations and once-weekly injectable options-are improving patient convenience, adherence, and overall long-term outcomes.

Challenges:
Despite their therapeutic benefits, several factors constrain the widespread adoption of GLP-1 receptor agonists. Gastrointestinal adverse effects, including nausea and vomiting, can negatively impact patient tolerance and adherence. While once-weekly injectable formulations enhance convenience, the need for subcutaneous administration remains a barrier for some patients. Oral therapies, such as oral semaglutide, have improved accessibility; however, there is an ongoing demand for ultra-long-acting agents that allow less frequent dosing. Additionally, the high cost of treatment and disparities in insurance coverage, particularly in low- and middle-income countries, limit broader market penetration and utilization.

Regional Trends:
The Asia-Pacific (APAC) region is emerging as one of the fastest-growing markets for GLP-1 receptor agonists, driven by increasing incidences of diabetes and obesity in countries such as China, India, and Japan. Market expansion is further supported by growing healthcare infrastructure, heightened focus on chronic disease management, and a substantial underserved patient population. Rising demand for innovative and effective metabolic disorder therapies is prompting leading pharmaceutical companies to strengthen their regional presence and invest in the development and commercialization of advanced GLP-1 receptor agonists, positioning APAC as a key growth frontier in the global market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2592

Recent Developments:
• In November 2023, The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
• In Dec 2021, Shanghai Innogen Pharma successfully completed a $120 million Series A funding round to support its Phase III trial of supaglutide, a GLP-1 agonist targeting diabetes. The funds will also be used to advance several first-in-class programs and establish a clinical trial manufacturing facility.

Segmentation of GLP-1 Market-
By Type of Molecule:
• Biologics
• Small Molecules
By Active Compound Used:
• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds
By Type of GLP-1 Agonist Drugs:
• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist
By Type of Agonist:
• Single agonist
• Dual agonist
• Tri-agonist
By Route of Administration:
• Oral
• Parenteral
By Target Indication:
• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/glp-1-market/2592

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.